Document is current
Any future updates will be listed below
-
Authors
Mokgokong, Ruth https://orcid.org/0000-0002-6278-4969
Cislo, Paul https://orcid.org/0009-0004-3130-2818
Tudone, Elena
Weinstein, Edward
Cappelleri, Joseph C. https://orcid.org/0000-0001-9586-0748
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05438602 at ClinicalTrials.govDocuments that mention this clinical trial
Symptom Alleviation/Resolution and Returns to Usual Health/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial
https://doi.org/10.1007/s40121-025-01228-w
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 3 July 2025
Accepted: 27 August 2025
First Online: 14 October 2025
Declarations
:
: Ruth Mokgokong is an employee and a minority shareholder of Pfizer, which funded this study. Paul Cislo is an employee and a minority shareholder of Pfizer, which funded this study. Elena Tudone is an employee and a minority shareholder of Pfizer, which funded this study. Edward Weinstein is an employee and a minority shareholder of Pfizer, which funded this study. Joseph C. Cappelleri is an employee and a minority shareholder of Pfizer, which funded this study.
: Ethics approval for the EPIC-IC protocol, amendments, and other relevant documents was granted by the appropriate institutional review boards and ethics committees (Supplementary Materials), as documented in Weinstein et al., 2025 [ ]. The study did not have a ‘master’ ethics committee or a main center; the principal investigator who signed the clinical study report was Dr. Roger Paredes, Hospital Germans Trias i Pujol, Spain. Participants provided written informed consent before enrolling in the study. The study was conducted in accordance with consensus ethical principles, including those in the Helsinki Declaration of 1964 and the Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines; with applicable International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) guidelines for Good Clinical Practice; and with applicable laws and regulations, including applicable privacy laws.
